SMARCB1‐deficient malignant neoplasm of the pancreas with heterogeneous morphologies that cannot be classified into existing histologic types

Yusuke Kouchi,Nozomu Sakai,Sakurako Harada‐Kagitani,Ryotaro Eto,Takashi Mishima,Shigetsugu Takano,Katsuhiro Nasu,Jun‐ichiro Ikeda,Masayuki Ohtsuka,Takashi Kishimoto

DOI: https://doi.org/10.1111/pin.13489

2024-10-30

Pathology International

Abstract:We report a case of 50‐year‐old Japanese male with SMARCB1‐deficient malignant pancreatic neoplasm whose morphologies were unique and heterogeneous. Immunohistochemical analysis revealed loss of SMARCB1 expression and fluorescence in situ hybridization detected heterozygous deletion of SMARCB1 for both the primary pancreatic tumor and metachronous liver metastasis. We could not classify our tumor into any of the existing entities, but recognition of such cases is important due to their metastatic capacities and the presence of some potential therapeutic options. A 50‐year‐old male with a pancreatic tail tumor underwent distal pancreatectomy. At 14 and 27 months after the primary surgery, metachronous liver metastases were identified and partial hepatectomies were performed for each. Pathologic findings of the primary pancreatic tumor were heterogeneous, but they essentially categorized into two components based on their cytologic features: (i) clear cell component and (ii) epithelioid cell component. The metastatic hepatic tumor was entirely composed of the epithelioid cell component. SMARCB1 expression was lost by immunohistochemistry and heterozygous deletion of SMARCB1 was identified by fluorescence in situ hybridization for both the primary and metastatic tumors. Targeted DNA sequencing of a metastatic hepatic tumor sample was performed and SMARCB1 loss was identified. Based on the morphologic, immunohistochemical, and molecular analyzes, the present case was difficult to classify into any of the existing entities. SMARCB1 deficiency might play a key role in the tumorigenesis.

pathology